Liu Xing-Han, Dai Zhi-Ming, Kang Hua-Feng, Lin Shuai, Ma Xiao-Bin, Wang Meng, Liu Kang, Dai Cong, Wang Xi-Jing, Dai Zhi-Jun
From the Department of Oncology (X-HL, H-FK, SL, X-BM, MW, KL, CD, X-JW, Z-JD); and Department of Anesthesia, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China (Z-MD).
Medicine (Baltimore). 2015 Dec;94(52):e2361. doi: 10.1097/MD.0000000000002361.
Although interleukin (IL)-23 receptor (IL-23R) plays an important role in the pathogenesis of multiple cancers, its association with cancer risk is inconsistent across different studies. We therefore conducted a meta-analysis with the aim of resolving the relationship among the 3 common polymorphisms of IL-23R (rs6682925, rs10889677, rs1884444) and cancer risk.Case-control studies evaluating the association between IL-23R polymorphisms (rs6682925, rs10889677, rs1884444) and cancer risk were searched in the PubMed, Web of Science, and CNKI databases.Data were included in the meta-analysis if they were from original studies adopting a case-control design investigating the association between IL-23R polymorphisms and risk of any cancer; all cancer cases must have been confirmed by histology or pathology, and controls selected from noncancer individuals. Case-only studies and review papers were excluded.Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the relationship of IL-23R polymorphisms (rs6682925, rs10889677, rs1884444) with cancer risk. A random-effects model or fixed-effects model was used depending on the heterogeneity of the data.Ultimately, 15 studies, involving 8784 cancer patients and 10,321 cancer-free controls, were included in our meta-analysis. In the overall analysis, the rs10889677 polymorphism was associated with breast cancer (BC) under the allelic, homozygous, dominant, and heterozygous models. Rs1884444 polymorphism was relevant to hepatocellular carcinoma (HCC) under the homozygous, recessive, and allelic models. However, no evidence of a relationship between IL-23R polymorphisms (rs6682925, rs10889677, rs1884444) and cancer risk was found in the overall population.Our meta-analysis provides no evidence supporting a global association of IL-23R polymorphisms (rs6682925, rs10889677, rs1884444) with the risk of cancer. However, rs10889677 may be associated with BC susceptibility and rs1884444 had association with HCC risk. Further large and well-designed studies are warranted to confirm this finding.
尽管白细胞介素(IL)-23受体(IL-23R)在多种癌症的发病机制中起重要作用,但其与癌症风险的关联在不同研究中并不一致。因此,我们进行了一项荟萃分析,旨在阐明IL-23R的3种常见多态性(rs6682925、rs10889677、rs1884444)与癌症风险之间的关系。
在PubMed、Web of Science和CNKI数据库中检索评估IL-23R多态性(rs6682925、rs10889677、rs1884444)与癌症风险关联的病例对照研究。
如果数据来自采用病例对照设计的原始研究,调查IL-23R多态性与任何癌症风险之间的关联,则纳入荟萃分析;所有癌症病例必须经组织学或病理学确诊,对照选自非癌症个体。排除病例系列研究和综述论文。
采用比值比(OR)和95%置信区间(CI)评估IL-23R多态性(rs6682925、rs10889677、rs1884444)与癌症风险的关系。根据数据的异质性使用随机效应模型或固定效应模型。
最终,我们的荟萃分析纳入了15项研究,涉及8784例癌症患者和10321例无癌对照。在总体分析中,rs10889677多态性在等位基因、纯合子、显性和杂合子模型下与乳腺癌(BC)相关。Rs1884444多态性在纯合子、隐性和等位基因模型下与肝细胞癌(HCC)相关。然而,在总体人群中未发现IL-23R多态性(rs6682925、rs10889677、rs1884444)与癌症风险之间存在关联的证据。
我们的荟萃分析没有提供证据支持IL-23R多态性(rs6682925、rs10889677、rs1884444)与癌症风险存在总体关联。然而,rs10889677可能与BC易感性相关,rs1884444与HCC风险相关。需要进一步开展大规模、设计良好的研究来证实这一发现。